Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series-Reference-Cited by-同舟云学术

Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series

Published:2022-09-23 Issue:6 Volume:32 Page:451-459
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Smith Jessica Louise,Menzies Alexander M.,Cohen Justine V.,Mut-Lloret Margarida,Ozgun Alpaslan,Spain Lavinia,Park John,Quach Henry T.,Pallan Lalit,McQuade Jennifer,Feng Sophie,Sandhu Shahneen,Atkinson Victoria,Tsai Katy,Long Georgina V.,Larkin James,Eroglu Zeynep,Johnson Douglas B.,Sullivan Ryan,Herkes Geoffrey K.,Henderson Andrew,Carlino Matteo S.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference16 articles.

1. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.;Hellmann;Lancet Oncol,2017

2. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.;Larkin;N Engl J Med,2015

3. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.;Motzer;N Engl J Med,2018

4. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.;Spain;Ann Oncol,2017

5. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors.;Feng;J Thorac Oncol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastases—Favorable Response after Immunotherapy Continued beyond Progression;Journal of Personalized Medicine;2024-01-12

2. Updates in toxicities associated with immune checkpoint inhibitors;Expert Review of Clinical Immunology;2023-06-05

3. Immune-globulin/ipilimumab/nivolumab;Reactions Weekly;2023-04-22